TSH Biopharm (ROCO:8432) Marketable Securities: NT$510 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:8432 TSH Biopharm Corp Ltd ROCO:8432
88 GF Score
Price NT$50.90
GF Value NT$75.14
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is TSH Biopharm Marketable Securities?

TSH Biopharm ROCO:8432 +0.59% 88 Marketable Securities is NT$510 Mil as of Mar. 2026. GuruFocus rates ROCO:8432 with a GF Score™ of 88/100 and a GF Value™ of NT$75.14 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. TSH Biopharm's Marketable Securities for the quarter that ended in Mar. 2026 was NT$510 Mil.

TSH Biopharm's annual Marketable Securities increased from Dec. 2023 (NT$196 Mil) to Dec. 2024 (NT$309 Mil) and increased from Dec. 2024 (NT$309 Mil) to Dec. 2025 (NT$468 Mil).

TSH Biopharm  (ROCO:8432) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

TSH Biopharm Marketable Securities Related Terms

TSH Biopharm Marketable Securities Historical Data

* Premium members only.

The historical data trend for TSH Biopharm's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TSH Biopharm Marketable Securities Chart

TSH Biopharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 351.52 326.86 195.54 309.02 467.74

TSH Biopharm Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 386.84 377.13 325.88 467.74 509.60
ROCO:8432
88GF Score
TSH Biopharm Corp Ltd ROCO:8432
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TSH Biopharm Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of NT$510 Mil mean?
TSH Biopharm (ROCO:8432) has a Marketable Securities of NT$510 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on TSH Biopharm and its competitors.
Is TSH Biopharm's Marketable Securities too high?
TSH Biopharm's current Marketable Securities is NT$510 Mil. Overall, TSH Biopharm has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TSH Biopharm's Marketable Securities compare to ZTS?
TSH Biopharm's Marketable Securities of NT$510 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on TSH Biopharm and its competitors. TSH Biopharm's current Marketable Securities is NT$510 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TSH Biopharm stock overvalued right now?
Based on GuruFocus' analysis, TSH Biopharm (ROCO:8432) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$75.14, compared to a current price of NT$50.90 — trading 32.3% below its estimated fair value. The current Marketable Securities is NT$510 Mil. TSH Biopharm's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For TSH Biopharm (ROCO:8432), the current Marketable Securities is NT$510 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TSH Biopharm (ROCO:8432) Overvalued in 2026?

Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued. The current stock price of NT$50.90 is trading 32.3% below its estimated GF Value™ of NT$75.14. GuruFocus considers TSH Biopharm to be Significantly Undervalued.

Key valuation signals for ROCO:8432:

  • Marketable Securities: NT$510 Mil
  • GF Value™: NT$75.14 vs. price of NT$50.90 (32.3% below fair value)
  • GF Score™: 88/100 with 2 warning signs

No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TSH Biopharm Business Description

Address No.3-1, Park Street, 3rd Floor-1, Nangang District, Taipei, TWN, 115
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
88GF Score

Get the complete analysis for ROCO:8432

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$50.90
Price
NT$75.14
GF Value